BioLineRx Ltd. (BLRX) stock surged by 5.7% at the last trading close while the BLRX stock price continued to rise by 3.24% in the pre-market trading session. BioLineRx Ltd. is an oncology-focused late-stage biopharmaceutical firm. The business strategy of BioLineRx is to in-license novel drugs, improve them across clinical phases, and then collaborate with pharmaceutical firms for further clinical production and/or commercialization.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
What is happening?
BLRX revealed on April 15, 2021, that it had submitted a poster at the AACR Annual Meeting, which will be held on a simulated basis from April 10-15, 2021. The poster, titled “A Multi-Center Phase 2a Trial of the CXCR4 Inhibitor Motixafortide (BL-8040) in Combination with Pembrolizumab and Chemotherapy, in Patients with Metastatic Pancreatic Adenocarcinoma, the COMBAT Study,” contains new analyses from the Company’s Phase 2a COMBAT/KEYNOTE-202 triple combination research of motixafortide in metastatic pancreatic cancer.
In the COMBAT/KEYNOTE-202 trial, patients with advanced pancreatic ductal adenocarcinoma, or PDAC, were given BioLineRx’s lead therapeutic candidate, motixafortide, in conjunction with KEYTRUDA® and chemotherapy.
Official Statements
Dr. Abi Vainstein, Chief Medical Officer of BioLineRx said that Liver metastases are a major factor in patients with metastatic PDAC having a bad prognosis. BLRX is delighted to present this additional review, which improves the findings announced from the COMBAT/KEYNOTE-202 trial in December 2020, since not only were nearly all patients diagnosed with stage 4 disease at the outset, but the overwhelming majority (80%) of the patients still had liver metastases, highlighting the study’s exceedingly challenging patient population. These findings should be replicated in a clinical experiment, and BLRX team is already working hard to determine the program’s next steps with future partnership collaborators.
